While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
Catching you up on the stories you need to know this morning, mass shooting victims testify on Capitol Hill, the White House outlines its plan to vaccinate kids younger than five years old, and we break down how to protect yourself from monkeypox.
The pharmaceutical giant Moderna says its updated 'bivalent' booster shot provides a stronger immune response against the Omicron variant of COVID-19 specifically. This week, Moderna plans to submit preliminary data to U.S. health officials in the hopes that its new booster will be available later this summer. Dr. Sampson Davis, emergency medicine physician, joins Cheddar News to discuss.
NASA has announced that the first official full-color images will be beamed back to Earth from the James Webb Telescope on July 12. Gregory L. Robinson, the director of the James Webb Space Telescope Program in the NASA Science Mission Directorate, joined Cheddar News to discuss the anticipated image drop. “We expect to see the universe different," he said. "Webb will allow us to see much, much clearer and deeper into the universe."
On this episode of Cheddar Reveals, Professor Laurence Hurst, Director of The Milner Centre for Evolution, discusses the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up? Neville Sanjana, faculty member at NY Genome and New York University, breaks down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases; Cheddar gets a look at Curiosity Stream's 'The Butterfly Effect.'
Neville Sanjana, faculty member at NY Genome and New York University, joins Cheddar Reveals to break down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases.
Professor Laurence Hurst, Director of The Milner Centre for Evolution, joins Cheddar Reveals to discuss the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up?
It can be tough to make sustainable choices, and even harder when sustainable materials don't hold up. Loliware has a solution to the plastic straw problem: its seaweed-based straws are stronger than paper alternatives and once used, can be composted and return to the earth or sea without causing harm. Sea Briganti, CEO of Loliware, joins Closing Bell to discuss the tech behind the straws, new product launches, and more.
Umbilical cord blood banking platform Anja Health raised $4.5 million dollars in a seed round led by Seven Seven Six, a venture capital firm founded by Reddit co-founder Alexis Ohanian. Anja Health offers a personalized, doctor-backed cord blood bank, which lets new parents freeze stem cells from their child's umbilical cord so they can be used to treat diseases in the future. It's a process Anja has called 'Hollywood's best-kept secret,' as celebrities like Kylie Jenner, Serena Williams, and more have all banked their umbilical cord blood. Kathryn Cross, the founder of Anja Health, joins Cheddar News' Closing Bell to discuss.
After learning that the suspect in the Uvalde school shooting posted about his intentions on Facebook, activists are urging social networks to make changes. Lena Derhally, a licensed psychotherapist and author of "The Facebook Narcissist," joined Cheddar News to discuss the role social media plays in school shootings. "They're not really invested in taking down hateful content," she said about social platforms."In regards to the shooting, it was 15 minutes before that actual threat. It would be pretty hard for a social media company to trace that threat that quickly. But what they can do better is take down threats and hateful content much faster and more than they're doing now."
Esper Bionics CEO Dima Gazda breaks down how they're creating a mind-controlled bionic hand that guest smarter the more you use it, and what this innovation means for the future of the prosthetics industry.
